Joel Isaacson & Co., LLC Biogen Inc. Transaction History

Joel Isaacson & Co., LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 26, 2023	SELL	$275.25 - $318.06 $34,131 - $39,439	-124 Reduced 14.29%	744 $211,000
Q3 2022 Oct 13, 2022	BUY	$194.69 - $268.46 $168,990 - $233,023	868 New	868 $232,000
Q1 2022 Apr 21, 2022	SELL	$193.77 - $244.14 $170,130 - $214,354	-878 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$259.0 - $414.71 $25,900 - $41,471	100 Added 12.85%	878 $304,000
Q1 2021 Apr 23, 2021	BUY	$242.95 - $284.63 $189,015 - $221,442	778 New	778 $218,000
Q4 2020 Jan 22, 2021	SELL	$236.26 - $355.63 $183,810 - $276,680	-778 Closed	0 $0
Q2 2020 Jul 21, 2020	BUY	$258.66 - $342.55 $2,845 - $3,768	11 Added 1.43%	778 $208,000
Q1 2020 Apr 21, 2020	BUY	$268.85 - $341.04 $2,688 - $3,410	10 Added 1.32%	767 $243,000
Q4 2019 Jan 24, 2020	BUY	$220.06 - $304.07 $166,585 - $230,180	757 New	757 $225,000

1,006

129M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Joel Isaacson & Co., LLC, based on Form 13F filings with the SEC.

Stay updated on Joel Isaacson & Co., LLC with notifications on news.